+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Continuous Glucose Monitoring Market Report by Component, End-User, Regions and Company Analysis 2024-2032

  • PDF Icon

    Report

  • 185 Pages
  • June 2024
  • Region: Global
  • Renub Research
  • ID: 5978754
Continuous Glucose Monitoring Market turned into US$ 6.32 Billion in 2023 and is projected to reach US$ 13.06 Billion by 2032, with a Compound Annual Growth Rate of 8.40% from 2024 to 2032.

Continuous glucose monitoring is an effective tool that mechanically estimates blood glucose levels at day and night. It contains 3 components: a tiny sensor, a sticky patch, and an implantable sensor. These sensors estimate the glucose stage inside the fluid between cells, which carefully mirrors the glucose stage within the blood. The CGM machine, additionally, consists of three parts: a sensor, a transmitter, and a software program. The transmitter wirelessly sends the data to smartphone. The CGM additionally offers alerts and shows an image that suggests the glucose level. Importantly, by helping to maintain glucose levels in a healthy range, CGM plays an essential role in stopping diabetes problems. The CGM is only used once a day, or nearly every day.

Impact of diabetes globally

Diabetes is an extreme health issue affecting millions of humans worldwide.
  • Currently, there are 537 million adults living with diabetes, and this number is expected to increase to 643 million by 2030 and 783 million by 2045.
  • Almost half of adults with diabetes (44%) are undiagnosed, equating to 240 million people. The majority have type 2 diabetes.
  • Over 75% of people with diabetes reside in low and middle-income countries.
  • It is estimated that over 1.2 million children and adolescents aged between 0-19 years suffer from type 1 diabetes.
  • In 2021, diabetes was responsible for 6.7 million deaths.
  • Diabetes accounted for a minimum of $ 966 Billion in healthcare spending in 2021, representing 9% of the global total.
  • High blood glucose during pregnancy affects one in six live births (21 million).

CGM User by Country

  • As of March 2023, approximately 2.4 million people in the United States are utilizing continuous glucose monitors.
  • In December 2022, 200,000 UK patients were using non-invasive glucose monitoring devices, up a third since spring.
  • In 2023, 61.9% of women and 58% of men in Germany will use continuous glucose monitors (CGMs).
  • In April 2023, The CGM penetration rate for type 1 diabetes in China was 6.9% and is expected to reach 38% by 2030.
  • In 2021, Approximately 33.9% of Japanese people utilize Continuous Glucose Monitors (CGMs).
  • In 2023, Over half (53.1%) of the total cohort of type 1 diabetes patients in India use a continuous glucose monitoring (CGM) device, according to a study by Mary Ann Liebert Inc.

China CGM Market

Diabetes has spread swiftly over the past decade because of adjustments in lifestyle and an ageing population. By 2045, it's envisioned to have an effect on 629 million people globally. China already has the largest range of diabetes sufferers (114.4 million) and is expected to attain 48%. According to The Lancet Regional Health, the costs of diabetes in China will boom from $250.2 Billion to $460.4 Billion throughout 2020-2030, with an annual increase rate of 6.32%.

Abbott Laboratories released a device called FreeStyle Libre 3 on April 2023. It is a hand-held device that shows real-time glucose readings from a sensor worn at the top of the of the arm. This enables diabetes patients to control their situation by viewing their glucose readings on a huge, vivid screen.

Continuous Glucose Monitoring Company Analysis

Continuous monitoring industry consists of several key players, consisting of Dexcom Inc., Ypsomed AG, Abbott Laboratories, Senseonics Holdings, Inc., Nemaura Medical, Inc., Medtronic, Inc., Tandem Diabetes Care, and Nova Biomedical.

Continuous Glucose Monitoring Company News

  • The Dexcom Stelo Glucose Biosensor System has been approved by the FDA for OTC sale, making it the first OTC continuous glucose monitor in 2024.
  • In January 2024, Medtronic's MiniMed 780G system now features Simplera Sync, a disposable continuous glucose monitor that eliminates the need for fingerstick. It offers a simple two-step insertion process and is half the size of previous Medtronic sensors, providing an improved user experience.
  • In 2023, Abbott Labs reported that FreeStyle Libre, its flagship CGM.
  • In June 2023, I-SENS launched CareSens Air, a compact glucose monitoring device approved by the South Korean Ministry. It functions for 15 days and has a calibration mechanism for accurate readings.
  • In March 2023 - the Eversense E3 CGM System offers real-time glucose values and trends via a mobile app.

Component - Market breakup in 3 viewpoints:

1. Sensors
2. Transmitters
3. Receivers

End-User - Market breakup in 3 viewpoints:

1. Hospitals
2. Homecare Settings
3. Others

Countries - Market breakup in 25 viewpoints:

1. North America
1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 United Arab Emirates
5.3 South Africa
6. Rest of the World

All the Key players have been covered from 3 Viewpoints:

  • Overview
  • Recent Development
  • Revenue Analysis

Company Analysis:

1. Dexcom Inc.
2. Ypsomed AG,
3. Abbott Laboratories
4. Senseonics Holdings, Inc.
5. Nemaura Medical, Inc.
6. Medtronic, Inc.
7. Tandem Diabetes Care
8. Nova Biomedical

Table of Contents

1. Introduction2. Research Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Continuous Glucose Monitoring Market
6. Market Share - Global Continuous Glucose Monitoring Analysis
6.1 By Component
6.2 By End User
6.3 By Country
7. Component - Global Continuous Glucose Monitoring Market
7.1 Sensors
7.2 Transmitters
7.3 Receivers
8. End-User - Global Continuous Glucose Monitoring Market
8.1 Hospitals
8.2 Homecare Settings
8.3 Others
9. Countries - Global Continuous Glucose Monitoring Market
9.1 North America
9.1.1 United States
9.1.2 Canada
9.2 Europe
9.2.1 France
9.2.2 Germany
9.2.3 Italy
9.2.4 Spain
9.2.5 United Kingdom
9.2.6 Belgium
9.2.7 Netherlands
9.2.8 Turkey
9.3 Asia Pacific
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 South Korea
9.3.5 Thailand
9.3.6 Malaysia
9.3.7 Indonesia
9.3.8 Australia
9.3.9 New Zealand
9.4 Latin America
9.4.1 Brazil
9.4.2 Mexico
9.4.3 Argentina
9.5 Middle East & Africa
9.5.1 Saudi Arabia
9.5.2 United Arab Emirates
9.5.3 South Africa
9.6 Rest of the World
10. CGM Reimbursement Policy
11. Porters Five Forces
11.1 Bargaining Power of Buyer
11.2 Bargaining Power of Supplier
11.3 Threat of New Entrants
11.4 Rivalry among Existing Competitors
11.5 Threat of Substitute Products
12. SWOT Analysis
12.1 Strengths
12.2 Weaknesses
12.3 Opportunities
12.4 Threats
13. Key Players Analysis
13.1 Dexcom Inc
13.1.1 Overview
13.1.2 Key Persons
13.1.3 Product Analysis
13.1.4 Recent Development
13.1.5 Revenue
13.2 Ypsomed AG
13.2.1 Overview
13.2.2 Key Persons
13.2.3 Product Analysis
13.2.4 Recent Development
13.2.5 Revenue
13.3 Abbott Laboratories
13.3.1 Overview
13.3.2 Key Persons
13.3.3 Product Analysis
13.3.4 Recent Development
13.3.5 Revenue
13.4 Senseonics Holdings, Inc.
13.4.1 Overview
13.4.2 Recent Development
13.4.3 Revenue
13.5 Nemaura Medical, Inc.
13.5.1 Overview
13.5.2 Key Persons
13.5.3 Product Analysis
13.5.4 Recent Development
13.5.5 Revenue
13.6 Medtronic, Inc.
13.6.1 Overview
13.6.2 Key Persons
13.6.3 Product Analysis
13.6.4 Recent Development
13.6.5 Revenue
13.7 Tandem Diabetes Care
13.7.1 Overview
13.7.2 Key Persons
13.7.3 Product Analysis
13.7.4 Recent Development
13.7.5 Revenue
13.8 Nova Biomedical
13.8.1 Overview
13.8.2 Key Persons
13.8.3 Product Analysis
13.8.4 Recent Development
13.8.5 Revenue

Companies Mentioned

  • Dexcom Inc.
  • Ypsomed AG,
  • Abbott Laboratories
  • Senseonics Holdings, Inc.
  • Nemaura Medical, Inc.
  • Medtronic, Inc.
  • Tandem Diabetes Care
  • Nova Biomedical

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Table Information